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There has been a longstanding, worldwide interest in using regulatory
practices to deal with tobacco products.' Over the past twenty-five years, there have
been many significant advances in areas such as tobacco product taxation,
2
reduction of sales outlets for tobacco products,
3 prevention of sales to minors,4
advertising and promotion restrictions, 5 package warnings, 6 enforcement of smoke-
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1. See generally LUK JOOSSENS, WORLD HEALTH ORG., REGULATION OF TOBACCO PRODUCTS:
AN UPDATE ON EUROPEAN DEVELOPMENTS 1999-2001, at 1-10 (2001), available at
http://www.euro.who.int/document/e74524.pdf; WORLD HEALTH ORG., MONOGRAPH: ADVANCING
KNOWLEDGE ON REGULATING TOBACCO PRODUCTS, 59-64 (2001), available at
http://www.who.int/tobacco/media/en/OsloMonograph.pdf, MITCHELL ZELLER, WORLD HEALTH ORG.,
REGULATION OF TOBACCO PRODUCTS 2-8 (2000), available at
http://www.who.int/tobacco/media/en/ZELLER2000X.pdf
2. AM. LUNG ASS'N, STATE LEGISLATED ACTIONS ON TOBACCO ISSUES: 2005, at vi (2005),
available at http://slati.lungusa.org/reports/SLATI 05.pdf; RICHARD McGOWAN, BUSINESS, POLITICS,
AND CIGARETTES 79 (1995) ("The measure that government at all levels has employed most frequently
to discourage the sale of cigarettes is the cigarette excise tax.").
3. E.g., Smoke-Free Ontario Act, 1994 S.O., ch. 10 § 4 (Ont.), available at
http://www.health.gov.on.ca/english/public/updates/archives/hu_05/smoke freeOntario_act.pdf,
Tobacco Control Act, S.S., ch.T-14.1 § 8 (2001), amendedby 2002 S.S., ch. R-8.2 § 97 & 2004 S.S., ch.
51 § 6 (Sask.), available at http://www.qp.gov.sk.ca/documents/english/Statutes/Statutes/tl4-1.pdf.
4. JESSICA KUEHNE & ERIC LINDBLOM, CAMPAIGN FOR TOBACCO-FREE KIDS, ENFORCING LAWS
PROHIBITING CIGARETTE SALES TO KIDS REDUCES YOUTH SMOKE 1 (2007), available at
http://tobaccofreekids.org/research/factsheets/pdf/0049.pdf ("Efforts to reduce illegal cigarette sales to
kids can have a direct impact on roughly three-quarters or more of all cigarettes smoked by kids.").
5. Marc C. Willemsen & Boudewijn de Blij, GLOBALink, Tobacco Control Factsheets: Tobacco
Advertising, http://factsheets.globalink.org/en/advertising.shtml (last visited Jan. 17, 2008).
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free spaces, 7 and regulation of cigarettes for fire safety.8 Yet, cigarette smoking
continues to be the largest cause of preventable death 9 even in countries like
Canada, where per capita cigarette consumption has been driven down by over
60%.1° Furthermore, the World Health Organization (WHO) estimates that tobacco
smoke will have caused nearly one billion deaths this century."' Therefore, some
key questions remain about the direction of regulatory policy and how we might
further reduce tobacco's toll.
I. THE CHALLENGE
It is worth noting that many people consider death and disease from smoking
a medical problem12 and have trouble understanding the need for legal interference.
However, there are many ways that (and many reasons why) the law can be used in
advancing a public health agenda. It is important to point out that in the history of
public health, discovering the cause of a health problem has been a medical or
scientific question, but acting on such a discovery raises social, political, and legal
issues. Major scientific breakthroughs, like the role of sanitation,13 immunization, 4
safe food preparation,' 5 and effective drug treatments, 16 have created public health
breakthroughs that are only fully achieved when policies are changed to reflect
6. ROB CUNNINGHAM, CAN. CANCER SOC'Y, PACKAGE WARNINGS: OVERVIEW OF
INTERNATIONAL DEVELOPMENTS 1 (2007), available at http://www.smoke-
free.ca/wamings/WamingsResearch/ReleaseWarningLabels 20070320.pdf.
7. E.g., Mark Levin, Tobacco Industrial Policy and Tobacco Control Policy in Japan, 6 ASIAN-
PAC. L. & POL'Y J. 44, 51 (2005) (discussing the proliferation of smoke-free spaces across Japan).
8. HILLEL R. ALPERT, TOBACCO CONTROL LEGAL CONSORTIUM, REGULATING CIGARETTES FOR
FIRE SAFETY passim (2007), available at
http://www.firesafecigarettes.org/assets/files//RegulatingCigsforFireSafety05O7.pdf.
9. CTRS. FOR DISEASE CONTROL, DEP'T OF HEALTH & HUMAN SERVS., TARGETING TOBACCO
USE: THE NATION'S LEADING CAUSE OF PREVENTABLE DEATH 2 (2007), available at
http://www.cdc.gov/nccdphp/publications/aag/pdf/osh.pdf; World Health Org., An International Treaty
for Tobacco Control (Aug. 12, 2003), http://www.who.int/features/2003/08/en/.
10. See ROB CUNNINGHAM, SMOKE & MIRRORS: THE CANADIAN TOBACCO WAR 16-17 figs.3 & 4
(1996); Canadian Trends in Historical Per Capita Cigarette Consumption (Age 15+), 1921-2005 (on file
with author).
11. Ed Cropley, Smoking Could Kill 1 Billion This Century - WHO, REUTERS, July 2, 2007,
available at http://www.reuters.com/article/latestCrisis/idUSBKK252060.
12. See, e.g., Atiya Dhala et al., Respiratory Health Consequences of Environmental Tobacco
Smoke, 88 MED. CLINICS N. AM. 1535 passim (2004) (discussing the major health problems associated
with tobacco smoke).
13. GEORGE E. WARING, JR., DRAINING FOR PROFIT AND DRAINING FOR HEALTH 222-23 (New
York: Orange Judd & Co. 1893) (1867).
14. E.g., JONATHAN B. TUCKER, SCOURGE: THE ONCE AND FUTURE THREAT OF SMALLPOX 3-4
(2001) (demonstrating that vaccinations eradicated the infectious disease of small pox).
15. E.g., JAMES HARVEY YOUNG, PURE FOOD: SECURING THE FEDERAL FOOD AND DRUGS ACT OF
1906 136-45 (1989) (discussing the health risks posed by adding preservatives to food).
16. E.g., HIV/AIDS PROGRAMME, WORLD HEALTH ORG., ANTIRETROVIRAL THERAPY FOR HIV
INFECTION IN ADULTS AND ADOLESCENTS 7, 11-12 (2006).
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these advances in knowledge. Using regulatory interventions to prevent diseases
caused by smoking is simply following in the footsteps of past public health battles.
Regulatory policies for tobacco products should focus on the ultimate public
health goal of the reduction of death, injury, and disease. 17 As with other public
health measures (e.g., the control of venereal diseases, 18 alcohol policies,' 9 drug
issues, and birth control2!), there is often a strong tendency on the part of some
people to take moralistic approaches about the behavior of others rather than taking
pragmatic public health approaches aimed at reducing death, injury, and disease. In
the case of tobacco and nicotine, there is a strong abstinence-only contingent within
the anti-tobacco community that condemns any use of nicotine without apparent
concern for issues of relative risk and the potential to move users to far less toxic
22
alternative delivery systems.
If tobacco-caused illness is to be addressed through effective regulatory
policy, it is critically important that the focus be on pragmatic measures aimed at
reducing death, injury, and disease, rather than simply imposing moral judgments
on the actions of others. Indeed, there are four broad pillars of intervention for the
purpose of reducing death, injury and disease from any dangerous activity.2 3
Interventions can aim to: (1) prevent the onset of a dangerous behavior; (2)
encourage cessation of the behavior; (3) seek to reduce the risk the behavior inflicts
on third parties; and (4) attempt to reduce risks for those who continue to engage in
the behavior.24
There is a similarly broad range of strategies that can be used in an effort to
apply law to achieve the goal of reduced health impact via these four broad areas of
17. See generally David Sweanor et al., Editorial, Tobacco Harm Reduction: How Rational Public
Policy Could Transform a Pandemic, 18 INT'L J. DRUG POL'Y 70, 70 (2007) (encouraging public
intervention to reduce the risk of death, injury, or disease from tobacco smoke).
18. ALLAN M. BRANDT, No MAGIC BULLET: A SOCIAL HISTORY OF VENEREAL DISEASE IN THE
UNITED STATES SINCE 1880, at 6 (1985) ("[T]he social and cultural uses of venereal disease as a means
of controlling sexuality have greatly complicated attempts to deal effectively with diseases from a
therapeutic standpoint.").
19. EDWARD BEHR, PROHIBITION: THIRTEEN YEARS THAT CHANGED AMERICA 21 (1996).
20. MICHAEL MASSING, THE FIx 85-86 (1998).
21. JACK HOLLAND, MISOGYNY 236-37 (2006).
22. Brad Rodu & William T. Godshall, Tobacco Harm Reduction: An Alternative Cessation
Strategy for Inveterate Smokers, HARM REDUCTION J., Dec. 2006, at 37,
http://www.harmreductionjoumal.com/content/pdf/1477-7517-3-37.pdf ("In effect, the status quo in
smoking cessation presents smokers with just two unpleasant alternatives: quit or die."); Philip Alcabes,
Editorial, Blowing Smoke About Tobacco, WASH. POST, May 30, 2006, at Al 7 (comparing the more
lenient policy approaches to regulating risky behavior regarding motorcycle helmets and condoms to the
no tolerance policy approach dealing with tobacco use); World Health Org., Tobacco Free Initiative,
100% Smoke-free is the Only Answer,
http://www.who.int/tobacco/communications/events/wntd/2007/smoke-free/en/index.htm (last visited
Jan. 19, 2008).
23. Sweanor et al., supra note 17.
24. Id.
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public health intervention. Once again, we can group the strategies into four general
areas. The first area deals with accessibility. This area includes measures that
impact the relative accessibility of different tobacco products and tobacco
dependence treatment products. To reduce the accessibility of tobacco products,
the law has been used to adjust the taxes on various tobacco/nicotine products, 26
restrict the locations where various products are sold, prevent sales to minors,27 ban
vending machines, 28 prohibit the distribution of free samples, 29 and increase the
accessibility of products that can assist smoking cessation.
30
A second strategic area is the promotion of informed choice. While there are
limitations on consumer sovereignty when dealing with addictive products, the law
has still played a huge role in many areas, such as dealing with misleading
advertising and promotion, 31 and requiring detailed package health messages and
disclosure of product ingredients.32 The pursuit of informed choice for consumers
has also been facilitated through the approval of an ever-wider range of tobacco
dependence treatment products for a growing range of indicated uses. 3 3 In recent
years there has also been increased interest in dispelling myths about nicotine itself
(many smokers believe it to be a huge health risk) and in ending the misleading
information that causes smokers to believe that some alternative products (such as
medicinal nicotine and various types of smokeless tobacco) are not significantly
less toxic than cigarette smoking.34
The third broad area of strategy in achieving health gains through legal
measures is obtaining the protection of third parties. As a result of several
municipal, state or provincial, and federal laws, as well as various litigation and
administrative interventions, governments have enforced a wide range of
protections against environmental tobacco smoke (also known as second-hand
25. Dorothy K. Hatsukami et al., Reducing Tobacco Harm: Research Challenges And
Issues, 4 NICOTINE & TOBACCO RES. S89, S93 (2002).
26. Michelle Leverett et al., Tobacco Use: The Impact of Prices, 30 J.L. MED. &
ETHICS 88, 88-89 (2002).
27. KUEHNE & LINDBLOM, supra note 4.
28. Jean L. Forster & Mark Wolfson, Youth Access to Tobacco: Policies and Politics, 19 ANN.
REV. PUB. HEALTH 203, 206 (1998).
29. AM. LUNG ASS'N, supra note 2, at vii.
30. See, e.g., Tamar Nordenberg, It's Quittin' Time, FDA CONSUMER, Nov.-Dec. 1997, at 19, 20
("For many smokers who want to quit, willpower alone isn't enough to beat the yearning. For them,
smoking cessation products the Food and Drug Administration has approved may reduce the cravings
and other withdrawal symptoms.").
31. Richard Craswell, Taking Information Seriously: Misrepresentation and Nondisclosure in
Contract Law and Elsewhere, 92 VA. L. REV. 565, 588-89 (2006).
32. PETER D. JACOBSON & JEFFREY WASSERMAN, TOBACCO CONTROL LAWS 7 (1997).
33. See Nordenberg, supra note 30, at 20-23.
34. See, e.g., TOBACCO ADVISORY GROUP, ROYAL COLL. OF PHYSICIANS OF LONDON, PROTECTING
SMOKERS, SAVING LIVES 4-5 (2002).
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smoke), and have guaranteed broad protections in many countries.35 Further
regulatory measures, such as a requirement for reduced ignition propensity
cigarettes, have reduced the risk to third parties from other cigarette-related
injuries, like cigarette-caused fires. 36 Interestingly, protection of third parties is
already, at least partially, based on the recognition that it is possible to reduce the
overall harm caused by tobacco use without necessarily requiring complete
cessation.37
Finally, broad product regulatory standards can dramatically reduce the risks
associated with tobacco use. Aside from the requirement to reduce the ignition
propensity of cigarettes and the provision of greater access to smoking cessation
products, various jurisdictions are now starting to take a serious look at product
standards.38 This relatively late move to look at the products themselves is
seemingly anomalous to product standards that are based on the recognition of a
continuum of risk, which have traditionally played one of the greatest roles in
reducing many other public health risks.39 In addition, tobacco products containing
nicotine seem ideally suited for such interventions since the risk is virtually all due
to the delivery system rather than the nicotine itself.40 Most users smoke cigarettes
35. See, e.g., 20 U.S.C. §§ 6081, 6083 (2000) (codifying the Pro-Children Act of 1994 that
prohibits smoking in many types of facilities that routinely provide services to children, such as
libraries, day care facilities and elementary schools); 49 U.S.C. § 41706 (2000) (barring smoking on all
United States airline flights arriving in or departing from the United States); 41 C.F.R. § 102-74.315
(2004) (banning smoking from all offices owned or used by the executive branch of the federal
government); 49 C.F.R § 374.201 (2005) (prohibiting smoking on all buses transporting passengers on
an interstate service); Levin, supra note 7; Jordan Raphael, Note, The Calabasas Smoking Ban: A Local
Ordinance Points the Way for the Future of Environmental Tobacco Smoke Regulation, 80 S. CAL. L.
REV. 393, 393 (2007).
36. ALPERT, supra note 8, at 7 ("Almost 27% of the U.S. population and all of Canada will soon be
covered by fire-safe cigarette legislation. With other states and countries, including Australia, New
Zealand, and members of the European Union, potentially following suit, the trend may lead to total
U.S.-and eventually nearly global-coverage."); Health Canada, Reduced Ignition Propensity
Cigarettes, http://www.hc-sc.gc.ca/hl-vs/tobac-tabac/legislation/reg/ignition-aillumage/index-e.html
(last visited Jan. 18, 2008).
37. TOBACCO ADVISORY GROUP, ROYAL COLL. OF PHYSICIANS OF LONDON, HARM REDUCTION IN
NICOTINE ADDICTION 213 (2007), available at http://www.rcplondon.ac.uk/pubs/contents/4fc74817-
64c5-4105-951e-38239b09c5db.pdf; see also MICHAEL BLEWDEN, ACTION ON SMOKING & HEALTH,
DISCUSSION DOCUMENT AND POLICY/LITERATURE REVIEW 46 (2007),
http://www.sfc.org.nz/pdfs/gravitasreport.pdf (reducing exposure to toxic substances in tobacco products
protects both the smoker and third party).
38. E.g., C. EVERETT KooP & DAVID A. KESSLER, FINAL REPORT OF THE ADVISORY COMMITTEE
ON TOBACCO POLICY AND PUBLIC HEALTH app. 3 at A4 (1997) (recommending that all nicotine delivery
devices, whether produced by tobacco companies or by pharmaceutical companies, should be evaluated
and regulated by the FDA using a consistent set of standards).
39. See, e.g., Press Release, U.S. Food & Drug Admin., Pharmaceutical cGMPs for the 21st
Century: A Risk-Based Approach (Aug. 21, 2002), http://www.fda.gov/oc/guidance/gmp.html
(discussing the Food and Drug Administration's risk-based approach to product quality regulation).
40. Sweanor et al., supra note 17, at 71.
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for the nicotine, but they die from the smoke.4 1 Given the potential gains from
reducing the risks of the delivery system combined with the successes to date from
other tobacco control strategies, it is very likely that product regulation will become
the key area of legal intervention in the years ahead.
It is within an overall context of comprehensive regulatory policies aimed at
reducing the harms of tobacco use that we need to consider how best to apply harm
reduction principles to tobacco/nicotine products.42 Ignoring harm reduction is
simply not a viable option as there is no question that it is possible to provide
massively less toxic alternative products. The continuum of risk for tobacco
products is very pronounced, with the Royal College of Physicians of the United
Kingdom estimating that cigarettes are in the range of ten to one thousand times
more hazardous than various non-combustible tobacco products.43 Some markedly
less hazardous non-combustion nicotine delivering products are already on the
market,44 while others can be expected very soon, and most of the major tobacco
companies (along with many pharmaceutical and "alternative health" companies)
are entering the alternative nicotine market.4 5
Another important change in the world of tobacco-one often overlooked by
anti-tobacco campaigners-is that as tobacco companies have come to
acknowledge the addictive and deadly nature of cigarettes, 46 they have arguably
gained credibility and positioned themselves to take a seat at the table when
discussing what can be done to alleviate the harm. This is similar to when a
company that is a large carbon emitter accepts the scientific evidence on global
warming. This acceptance gives the company credibility when it says that it wants
to be "part of the solution. 4 7 Governments will have an obligation to listen to what
41. Id.
42. For an in-depth discussion of harm reduction principles, see Gerry V. Stimson, Editorial,
"Harm Reduction-Coming of Age": A Local Movement with Global Impact, 18 INT'L J. DRUG POL'Y
67 (2007).
43. TOBACCO ADVISORY GROUP, supra note 34, at 5. The term non-combustible tobacco refers to
smokeless tobacco products. SCOTr D. BALLIN, TOBACCO AND TOBACCO PRODUCTS 5 (2006), available
at http://www.tobaccoatacrossroads.com/tobacco/l1 .pdf.
44. E.g., Sweanor et al., supra note 17, at 71 (discussing the widespread use of "snus" (a smokeless
tobacco product) in Sweden and the corresponding low level of tobacco-related disease).
45. John M. Broder, Experts Envision Battle Between Drug and Tobacco Companies, N.Y. TIMES,
Oct. 1, 1997, at A14.
46. See, e.g., Philip Morris USA, Smoking & Health Issues: Cigarette Smoking and Disease,
http://www.philipmorrisusa.com/en/healthissues/cigarette smoking-and-disease.asp (last visited Jan.
18, 2008) ("Philip Morris USA ... agrees with the overwhelming medical and scientific consensus that
cigarette smoking causes lung cancer, heart disease, emphysema and other serious diseases in
smokers.").
47. E.g., bp.com, BP and Climate Change,
http://www.bp.com/genericsection.do?categoryld=6905&contentld=7030746 (last visited Jan. 19,
2008); ExxonMobil.com, Climate and Emissions,
http://www.exxonmobil.com/Corporate/energyclimate.aspx (last visited Jan. 19, 2008) ("Recognizing
[VOL. 1 1:83
THE BASIS OF A COMPREHENSIVE REGULATORY POLICY
these companies have to say about alternative methods of nicotine delivery, and
they will need to think of how to deal with the fact that there is a very strong basis
in science for believing that the harm caused by current cigarettes can be massively
reduced by alternative nicotine delivery systems. Anti-tobacco campaigners who
refuse to discuss harm reduction will merely be ensuring that they are not part of
the ongoing dialogue that will shape this key area of policy.
II. LESSONS FROM THE PAST
Preventing a billion deaths through intelligent policy interventions is not an
unattainable goal. Not only do we see the examples of the eradication or extensive
control of communicable diseases and the role of sanitation, 8 but there is also the
relatively recent example of the "Green Revolution" led by Norman Borlaug and
funded by philanthropic organizations in the United States.4 9
There have also been numerous examples of other transformations in the
provision of goods and services as harm reduction approaches were applied to
regulation. The enactment of regulations aimed at protecting consumers from
hazardous food, 5° drugs,51 and medical services 52 are prime examples of what could
potentially happen to the tobacco/nicotine market. The history of goods and
services shows that nothing arrives "regulated." Rather, over time there is an inter-
relationship between changes in various businesses and changes in the regulations
affecting these businesses. 53 Tobacco products were left behind as other products
and services "morphed" into the modern businesses of today. As evidenced by the
current debate in tobacco harm reduction, the tobacco industry is now also starting
to "morph."
Two hundred years ago, there was little to distinguish between a charlatan and
a medical professional.54 Over one hundred and fifty years ago, there was little
differentiation between processed foods that delivered nutrition and those that
delivered deadly infections. 55 One hundred years ago, there was no clear division
between science-based pharmaceutical products and "other substances, faked, or
the risk of climate change, we are taking actions to improve efficiency and reduce emissions in our
operations.").
48. See supra notes 13-16 and accompanying text.
49. JOEL L. FLEISCHMAN, THE FOUNDATION 115-24 (2007) (discussing the effects of the Green
Revolution and crediting it to saving a billion lives since the mid-1960s).
50. YOUNG, supra note 15, at 262-64.
51. PHILIP J. HILTS, PROTECTING AMERICA'S HEALTH: THE FDA, BUSINESS AND ONE HUNDRED
YEARS OF REGULATIONS 95 (2003).
52. Roy PORTER, QUACKS: FAKERS & CHARLATANS IN MEDICINE 206 (2000).
53. E.g., NaturalGas.org, The History of Regulation,
http://www.naturalgas.org/regulation/history.asp (demonstrating that regulating natural gas is the
product of 30 years of regulatory evolution).
54. See PORTER, supra note 52, at 193.
55. YOUNG, supra note 15, at 291-93.
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mixed with dangerous ingredients." 56 Fifty years ago, consumers were not able to
make adequate purchase decisions based on automobile safety because there were
no well-defined automobile safety standards.57
A pattern emerges when looking at how other industries have changed, and
the tobacco/nicotine market seems to be experiencing these patterned changes as
well. In general, as products or services become established, there is a proliferation
of new products as various companies seek a marketplace advantage.58 As the
examples above demonstrate, science also advances and allows the ability to
distinguish between products on the basis of a continuum of risk. This in turn
creates an opportunity to use regulatory standards to shape the overall marketplace.
Social reformers may then be influenced by the changes in the marketplace and
scientific understanding, and may move from an abstinence-only approach to an
approach aimed at maximum reduction in death, injury and disease.
III. THE WAY FORWARD
Reducing risks for continuing users of tobacco/nicotine products without
requiring abstinence should be integrated into public health campaigns. 59 The
application of harm reduction principles to public health issues has a very long and
successful history,60 and failure to apply these principles to tobacco policy would
be a public health failure of enormous significance. We know the projected death
toll from smoking based on current studies.61 From increased scientific
understanding, we also know more about the nature of nicotine addiction, and that
people often smoke as a form of self-medication to cope with numerous conditions
(schizophrenia, depression, anxiety, etc.). 62 Based on this knowledge, it is clear that
abstinence-only campaigns are not only unsupported by science, but also constitute
a denial of human rights.
63
56. HILTS, supra note 51, at xi.
57. PETER ASCH, CONSUMER SAFETY REGULATION 21, 127 (1988).
58. See, e.g., Neelie Kroes, Comm'r for Competition, Eur. Comm'n, Industrial Policy and
Competition in Law and Policy, Address at the Developments in European Law Dedicated to CFI
President Bo Vesterdorf, in 30 FoRDHAM INT'L L.J. 1401, 1410 (2007).
59. Alcabes, supra note 22.
60. Stimson, supra note 42, at 67-68.
61. E.g., Cropley, supra note II.
62. Louisa Degenhardt & Wayne Hall, The Relationship Between Tobacco Use, Substance-Use
Disorders and Mental Health: Results from the National Survey of Mental Health and Well-Being, 3
NICOTINE & TOBACCO RES. 225, 231-34 (2001).
63. See L. T. Kozlowski & B. Q. Edwards, "Not Safe" is Not Enough: Smokers Have a Right to
Know More Than There is No Safe Tobacco Product, 14 TOBACCO CONTROL, at ii3, ii3 (2005) (arguing
that abstinence-only messages violate the right to health relevant information, which is a human right
that is based on the principles of autonomy and self-determination and is supported by the Universal
Declaration of Human Rights).
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The answer is a regulated marketplace for nicotine delivering products that is
based on a pragmatic risk reduction strategy. It must combine efforts focused on
prevention, cessation and protection with serious efforts aimed to reduce risks for
continuing nicotine product users. 64 Such an approach has the ability to maximize
health gains and minimize the risks of any unintended consequences, like less toxic
tobacco products encouraging or prolonging smoking. Applying such a risk-
minimizing approach to nicotine delivery products also follows the examples set
over many years in the regulation of a myriad of other goods and services.65
We are dealing with a category of products that can be set out along a very
pronounced continuum of risk. There is a large risk differential between the use of
cigarettes and alternative nicotine delivery products.66 Further, this risk differential
may even be greater than some well-known reduced-harm mechanisms, like safety
features in automobiles, the .use of protective sports equipment in contact sports,
and airline safety enhancements. 67 The most pronounced difference in nicotine
delivery products is whether a product requires lung inhalation of combustion
products to deliver nicotine or if the product is a less toxic non-combustion
product.68 Even with non-combustion products there is a significant range of risks,
64. For more information regarding an alternative cessation strategy for continuing smokers, see
Rodu & Godshall, supra note 22.
65. See supra text accompanying notes 50-53.
66. See David T. Levy et al., The Relative Risks of a Low-Nitrosamine Smokeless Tobacco Product
Compared with Smoking Cigarettes: Estimates of a Panel of Experts, 13 CANCER EPIDEMIOLOGY,
BIOMARKERS & PREVENTION 2035, 2038 (2004) (finding that the use of low-nitrosamine smokeless
tobacco poses only 5% to 10% of the risk of smoking, or, in other words, a 90% reduction in relative
risk in comparison with smoking); Carol E. Gartner et al., Assessment of Swedish Snus for Tobacco
Harm Reductions: An Epidemiological Modeling Study, 369 LANCET 2010, 2012 (2007) (finding little
difference between the health-adjusted life expectancy between smokers who quit all tobacco use and
those who switched to snus). For more information regarding studies that have concluded that smokeless
tobacco use poses a lesser risk to users in comparison to cigarettes, see Rodu & Godshall, supra note 22.
67. Improvements in automobile safety, such as the use of seat belts, have reduced the risk of fatal
injury during accidents by about 50%. NAT'L HIGHWAY TRAFFIC SAFETY ADMIN., SAFETY BELTS AND
TEENS 2003 REPORT (2003), available at
http://www.nhtsa.dot.gov/people/injury/airbags/buasbteensO3/index.htm. Use of discretionary protective
equipment while playing sports has resulted in only an approximately 9% decrease in the overall rate of
lower extremity injury and a 19% decrease in the rate of game injury for all athletes. Jingzhen Yang et
al., Use of Discretionary Protective Equipment and Rate of Lower Extremity Injury in High School
Athletes, 161 AM. J. EPIDEMIOLOGY 511, 515 (2005). Because of new warning devices and other safety
enhancements adopted by the airline industry, the risk of a passenger dying on an airline jet flight from
2000 through 2005 was one flight in 22.8 million, a 60% drop from the 1990's. Alan Levin, Airways Are
the Safest Ever, USA TODAY, June 30, 2006, at 1A.
68. Karl Fagerstrom, The Nicotine Market: An Attempt to Estimate the Nicotine Intake from
Various Sources and the Total Nicotine Consumption in Some Countries, 7 NICOTINE & TOBACCO RES.
343,343-44, 349 (2005).
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but manufacturers have the ability to further reduce risks to consumers through
such measures as the reduction of tobacco-specific nitrosamines.
69
CONCLUSION
Product regulation can have various purposes. Regulations can be designed to
ban or standardize products, give a relative advantage to some politically favored
product, or reduce harm from the use of certain products. Regulations can
sometimes simultaneously pursue more than one of these goals. But if the goal is
reduction of death, injury and disease, product regulation must be narrowly focused
on reduction of harm. Regulators should replace the abstinence-only paradigm with
a pragmatic science-based public health approach that includes risk reduction
strategies for continuing users. With this approach, we can achieve a great advance
for global health.
69. See Levy et al., supra note 66, at 2038 (explaining that results from the article's study suggest
that low-nitrosamine smokeless tobacco products may be less hazardous than conventional cigarettes).
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